Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
$22.20
-7.0%
$21.61
$13.22
$62.74
$1.27B-1.69935,447 shs819,923 shs
Grifols, S.A. stock logo
GRFS
Grifols
$8.18
-0.6%
$7.31
$5.79
$9.96
$5.62B0.441.16 million shs680,695 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$35.14
-0.3%
$37.84
$15.16
$46.48
$5.58B2.212.98 million shs1.28 million shs
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
$16.93
+0.5%
$16.87
$13.61
$30.36
$5.72BN/A26,756 shs7,109 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-2.81%-3.28%+0.51%+20.43%-35.62%
Grifols, S.A. stock logo
GRFS
Grifols
+1.48%+2.36%+14.15%+3.65%+14.31%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+1.94%-0.65%-14.74%+20.11%+110.89%
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
+1.45%+2.68%-10.43%-12.29%+1,683,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
2.1841 of 5 stars
3.51.00.00.03.61.70.6
Grifols, S.A. stock logo
GRFS
Grifols
2.8665 of 5 stars
0.03.01.70.02.10.03.8
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.8049 of 5 stars
2.42.00.03.53.61.71.9
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
3.00
Buy$79.86259.72% Upside
Grifols, S.A. stock logo
GRFS
Grifols
3.50
Strong BuyN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$40.8016.11% Upside
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
3.00
Buy$22.0029.95% Upside

Current Analyst Ratings Breakdown

Latest GPCR, TLX, TGTX, and GRFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $75.00
5/2/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
4/22/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/12/2025
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/4/2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
2/28/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$9.77 per shareN/A
Grifols, S.A. stock logo
GRFS
Grifols
$7.21B0.78$0.86 per share9.54$12.55 per share0.65
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$386.39M14.44$0.10 per share353.90$1.06 per share33.15
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
$783.21M7.31N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/14/2025 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$64.20M$1.176.997.79N/AN/AN/AN/A7/28/2025 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$12.67M$0.24N/A35.14N/A-5.42%-8.32%-3.40%8/5/2025 (Estimated)
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/AN/A0.0035.27N/AN/AN/AN/AN/A

Latest GPCR, TLX, TGTX, and GRFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$0.24-$0.27-$0.03-$0.27N/AN/A
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
3/3/2025Q4 2024
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.08$0.15+$0.07$0.15$100.67 million$108.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
$0.364.40%N/A30.77%N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/A
27.63
27.63
Grifols, S.A. stock logo
GRFS
Grifols
1.11
2.26
0.79
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.27
4.59
3.91
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
13657.34 million51.86 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
26,300687.56 million686.25 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.76 million139.32 millionOptionable
Telix Pharmaceuticals Limited American Depositary Shares stock logo
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A337.97 millionN/AN/A

Recent News About These Companies

Telix shares crash 8% on US FDA blow
Telix Pharmaceuticals Ltd. ADR
Telix Reports US$186M Q1 Revenue, Up 62% YOY

New MarketBeat Followers Over Time

Media Sentiment Over Time

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$22.20 -1.66 (-6.96%)
Closing price 04:00 PM Eastern
Extended Trading
$22.60 +0.40 (+1.78%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Grifols stock logo

Grifols NASDAQ:GRFS

$8.18 -0.05 (-0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$8.20 +0.02 (+0.18%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$35.14 -0.10 (-0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$35.38 +0.24 (+0.68%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Telix Pharmaceuticals Limited American Depositary Shares stock logo

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$16.93 +0.09 (+0.53%)
Closing price 04:00 PM Eastern
Extended Trading
$16.75 -0.18 (-1.06%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.